Document is current

Article History

Received: 26 April 2019

Accepted: 26 September 2019

First Online: 8 November 2019

Ethics approval and consent to participate

: We declare that this study has been performed in accordance with Declaration of Helsinki and was approved by the appropriate local body. All participants have signed the informed consent form.

: Not applicable.

: JLC-B reports having received lecture fees from Eli Lilly. GMM is an investigator of the ALAFOS study at Eli Lilly and Company. NC is an investigator of the ALAFOS study at Eli Lilly and Company. She is also a speaker for Eli Lilly and Company; she has participated as a principal investigator in phase III clinical studies and has served on the advisory board for Eli Lilly and Company. She has received fees for research from Lilly. She has also participated in clinical studies as principal investigator and speaker for Merck Sharp & Dohme, Novartis of Colombia, Pfizer, Amgen, and Biopas. She has no employment relationship with any of these organizations. AM is a speaker for Lilly, Amgen and FARMA de Colombia. JFM is a speaker for Lilly and has received fees for research from Lilly. MLG is an investigator of the ALAFOS study at Eli Lilly and Company. She is also a speaker for Eli Lilly and Company. LGO is an investigator of the ALAFOS study at Eli Lilly and Company; he is also a speaker for Eli Lilly and Company and an author on publications from Eli Lilly and Eurofarma; he also serves on the advisory board of UCB (Belgian Chemical Union) and the board of directors for Eurofarma. MSC, ACC, VI, and SF are employees of Eli Lilly and Company.